




(IV)




(VII)




(VIII)




(IX)




(X)




(XIII)



(XV)



(XIX)







(XXV)

and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof and combinations thereof.

5. (Amended) A method of treating [disease] osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, premenstrual syndrome, prostatic carcinoma, benign prostatic hyperplasia, pulmonary hypertension, reperfusion damage, rheumatoid arthritis, osteoarthritis, seborrhea, senile gynecomastia, testosterone deficiency, Turner's syndrome, uterine fibrosis, atrophic vaginitis, incontinence, uterine cancer, hirsutism, bulimia, anorexia, hypoactive sexual desire, sexual arousal disorder, dyspareunia, vaginismus, prolapse, urinary tract infections, stroke, myocardial infarction, acute or chronic renal failure, peripheral arterial occlusive disease, Raynaud's Phenomenon, cancers of the ovary, liver, and pancreas, as well as desmoid cancer, glioma, and renal cell carcinoma, or promoting wound healing, increasing the frequency of orgasms, or

lowering vaginal pH comprising administering to a subject in need thereof, an effective amount of a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



wherein R<sub>1</sub> is selected from , , or 


NH(CH<sub>2</sub>)<sub>3</sub>COR<sub>6</sub>;

R<sub>5</sub> is selected from H, or CH<sub>3</sub>;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>7</sub> are the same or different and are selected from H and OR<sub>5</sub>; and


R<sub>6</sub> is selected from -OH, or -NHCH<sub>2</sub>COOH,

provided that:

- (a) if R<sub>1</sub> is , or -NH(CH<sub>2</sub>)<sub>3</sub>COOH and
- (b) R<sub>2</sub> is OH or OCH<sub>3</sub> and R<sub>3</sub> and R<sub>7</sub> are H, or if R<sub>1</sub> is as defined in (a) above and
- (c) R<sub>2</sub> and R<sub>7</sub> are H and R<sub>3</sub> is OH or OCH<sub>3</sub>,

then R<sub>4</sub> is not H;

and further provided that when R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>7</sub> are H, then R<sub>1</sub> is not

 or an optical, stereo, regio or configurational isomer or geometric

isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof.

An Information Disclosure Statement is being filed concurrently with this amendment. The examiner is requested to consider each document listed; however, applicants wish to highlight the following two publications: Proceedings: The 45<sup>th</sup> ASMS Conference on Mass Spectrometry and Applied Topics, June 1-5, 1997, Palm Springs, CA; and Proceedings: The 46<sup>th</sup> ASMS Conference on Mass Spectrometry and Applied Topics, May 31-June 4, 1998, Orlando, FL. A separate paper is attached hereto that details the status of the claims and sets forth the support for the claim changes.

Applicants believe that, in view of the amendments and remarks made above, this application is in condition for allowance. Reconsideration and allowance of claims 2, 5-10 is respectfully requested.

Date: 5/30/2003

By: Todd M. Crissey

Todd M. Crissey  
Registration No. 37,807  
Pfizer Inc.  
Patent Department,  
MS 8260-1611  
Eastern Point Road  
Groton, CT 06340  
Phone: (860) 715-4331  
Fax: (860) 441-5221

**Status of Claims and Support for Claim Changes**

Claim Number	Status of Claims	Support for Changes
1	canceled	
2	pending (amended)	Original claim 2 and compounds X, XIII and XV in Table 2, columns 13-14.
3	canceled	
4	canceled	
5	pending (amended)	Original claim 5 and column 16, lines 23-44.
6	pending	
7	pending	
8	pending	
9	pending	
10	pending	
11	cancel	